-
Product Insights
NewActivin Receptor Type 1 – Drugs In Development, 2024
The Activin Receptor Type 1 pipeline drugs market research report outlays comprehensive information on the Activin Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Musculoskeletal Disorders, Hematological Disorders, Oncology, and Toxicology which include indications of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Bone Disorders, Iron Deficiency Anemia, Anemia, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Chemotherapy...
-
Product Insights
NewActivin Receptor Like Kinase – Drugs In Development, 2024
The Activin Receptor Like Kinase pipeline drugs market research report outlays comprehensive information on the Activin Receptor Like Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Musculoskeletal Disorders, Hematological Disorders, Oncology, and Metabolic Disorders which include indications of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Post Menopausal Osteoporosis, Iron Deficiency Anemia, Anemia, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis (PPV-MF),...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: Pelabresib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Solid Tumor Drug Details: YS-ON-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vismodegib in Meningioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vismodegib in Meningioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vismodegib in Meningioma Drug Details: Vismodegib (Erivedge) belongs to the class of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vismodegib in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vismodegib in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vismodegib in Refractory Multiple Myeloma Drug Details: Vismodegib (Erivedge) belongs...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navtemadlin in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navtemadlin in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Navtemadlin in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glasdegib in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glasdegib in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glasdegib in Glioblastoma Multiforme (GBM) Drug Details: Glasdegib (Daurismo) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Germ Cell Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Germ Cell Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Germ Cell Tumors Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Dysgerminoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Dysgerminoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Dysgerminoma Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed...